BackZevra Therapeutics Overview

Zevra Therapeutics Accounts Payable

Latest accounts payable for KMPH: $0.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$0.00

Peer average

Loading

Zevra Therapeutics Accounts Payable History

Loading

Zevra Therapeutics vs. peers: Accounts Payable Comparison

Loading

Zevra Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zevra Therapeutics (KMPH) FAQ

As of the most recent data (March 2026), KMPH shows a accounts payable of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KMPH's accounts payable is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Zevra Therapeutics is outperforming or lagging.

Tracking KMPH's accounts payable over time shows whether Zevra Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Zevra Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $0) with ownership activity and broader fundamentals.

Zevra Therapeutics's accounts payable is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.